Urinary Excretion of Glucagon-Like Peptide 1 (GLP-1) 7-36 Amide in Human Type 2 (Non-Insulin-Dependent) Diabetes Mellitus

The urinary excretion of insulinotropic glucagon-like peptide 1 (GLP-1) was investigated as an indicator of renal tubular integrity in 10 healthy subjects and in 3 groups of type 2 diabetic patients with different degrees of urinary albumin excretion rate. No significant difference emerged between the groups with respect to age of the patients, known duration of diabetes, metabolic control, BMI, or residual beta-cell pancreatic function. Endogenous creatinine clearance was significantly reduced under conditions of overt diabetic nephropathy, compared with normo and microalbuminuric patients (p < 0.01). Urinary excretion of GLP-1 was significantly higher in normoalbuminuric patients compared to controls (490.4 ± 211.5 vs. 275.5 ± 132.1 pg/min; p < 0.05), with further increase under incipient diabetic nephropathy conditions (648.6 ± 305 pg/min; p < 0.01). No significant difference resulted, in contrast, between macroproteinuric patients and non-diabetic subjects. Taking all patients examined into account, a significant positive relationship emerged between urinary GLP-1 and creatinine clearance (p = 0.004). In conclusion, an early tubular impairment in type 2 diabetes would occur before the onset of glomerular permeability alterations. The tubular dysfunction seems to evolve with the development of persistent microalbuminuria. Finally, the advanced tubular involvement, in terms of urinary GLP1 excretion, under overt diabetic nephropathy conditions would be masked by severe concomitant glomerular damage with the coexistence of both alterations resulting in a peptide excretion similar to control subjects.

Key words:

Urinary GLP-1 Excretion - Tubular Dysfunction - Diabetic Nephropathy

References

• 1 Orskov C. Glucogon-like peptide 1, a new hormone of the entero-insular axis.  Diabetologia. 1992;  35 701-711
• 2 Jia X, Brown J C, Ma P, Pederson R A, McIntosh C HS. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (7-36) on insulin secretion.  Am J Physiol. 1995;  31 E645-E651
• 3 Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans.  J Clin Invest. 1996;  97 92-103
• 4 Edwards C MB, Todd J F, Mahmoudi M, Wang Z, Wang R M, Ghatei M A, Bloom S R. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Studies with the antagonist exendin 9-39.  Diabetes. 1999;  48 86-93
• 5 Orskov C, Andreasen J, Holst J J. All products of proglucagon are elevated in plasma from uremic patients.  J Clin Endocrinol Metab. 1992;  74 379-384
• 6 Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I. Renal catabolism of glucagon-like peptides 1 and 2.  Can J Physiol Pharmacol. 1990;  68 1568-1573
• 7 Ruiz-Grande C, Alarcon C, Alcantara A, Castilla C, Lopez Novoa J M, Villanueva-Penacarillo M L, Valverde I. Renal catabolism of truncated glucagon-like peptide 1.  Horm Metab Res. 1993;  25 612-616
• 8 Pontouch P, Jensen T, Deckert T, Ondrejka P, Mikulecky M. Urinary excretion of retinol-binding protein in type 1 (insulin-dependent) diabetic patients with microalbuminuria and clinical nephropathy.  Acta Diabetol. 1992;  28 206-210
• 9 Holm J, Hemmingsen L, Nielsen N V, Thomsen M. Increased urinary excretion of the retinol-binding protein in insulin-dependent diabetes mellitus in the absence of microalbuminuria.  Clinica Chimica Acta. 1987;  170 345-350
• 10 Holm J, Hemmingsen L, Nielsen N V. Relationship between the urinary excretion of albumin and retinol-binding protein in insulin-dependent diabetics.  Chimica Clinica Acta. 1988;  177 100-106
• 11 Mutti A, Alinovi R, Ghiggeri G M, Bergamaschi E, Candiano G, Rasi A, Gusmano R, Franchini I, Borghetti A. Urinary excretion of brush-border antigen and plasma proteins in early stages of diabetic nephropathy.  Chimica Clinica Acta. 1990;  188 93-100
• 12 Ellis E N, Brouhard B H, Lagrone L, Travis A B. Urinary excretion of N-acetyl-beta-D-glucosaminidase in children with type 1 diabetes mellitus.  Diabetes Care. 1983;  6 251-255
• 13 Jung K, Pergande M, Schimke E, Ratzmann K P, Ilius A. Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy.  Clin Chem. 1988;  343 544-547
• 14 Lugari R, Serra L, Poppi C, Baumgartl U, Gnudi A. Zandomeneghi R. Impaired urinary excretion of epidermal growth factor (EGF) in type 1 (insulin-dependent) diabetes mellitus.  Med Sci Res. 1994;  22 65-67
• 15 Mathiesen E, Naxo E, Hommel E, Parving H H. Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy.  Diabetic Medicine. 1989;  6 121-126
• 16 Dagogo-Jack S, Marshall S M, Kendall-Taylor P, Alberti K GMM. Urinary excretion of Human Epidermal Growth Factor in the various stages of diabetic nephropathy.  Clinical Endocrinology. 1989;  31 167-173
• 17 Mogensen C E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.  N Engl J Med. 1984;  310 356-360
• 18 Viberti G C, Jarret R J, Mahmud U, Hill R D, Argyropoulos A, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus.  Lancet. 1982;  1 1430-1432
• 19 Orsoni G, Frasca G M, Vangelista A, Bonomini V, Lugari R, Bonomini L, Tagliavini P, Gnudi A. Relationship between histological renal lesions and protein excretion in diabetic nephropathy.  Med Sci Res. 1991;  19 567-569
• 20 Chavers B M, Bilous R W, Ellis E N, Steffes M W, Mauer S M. Glomerular lesions and urinary albumin excretion in type 1 diabetes without overt proteinuria.  N Engl J Med. 1989;  320 966-970